CPI-0610

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Retrieved on: 
星期二, 九月 19, 2023
Genetic engineering, GBM, Cancer, Hope, NK, Cell, IP, HSCT, Pharmacotherapy, Food and Drug Administration Amendments Act of 2007, Leukemia, Patient, DRI, CPI-0610, Growth, FDA, Food, Deltex Medical Group, Vaccine, Pharmaceutical industry

IN8bio now holds 19 total granted U.S. and international patents, and numerous pending patent applications.

Key Points: 
  • IN8bio now holds 19 total granted U.S. and international patents, and numerous pending patent applications.
  • NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio.
  • The company was recently granted patents around the world that cover use of the combination of its proprietary DeltEx DRI platform with CAR-T and CPI’s.
  • IN8bio boasts a strong IP portfolio of granted patents encompassing the DRI, CAR-T and HSCT families, with multiple additional applications pending globally to further expand its patent portfolio and IP position.

Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
星期二, 三月 14, 2023
Research, AACR, Abstract, CPI-0610, Uveal melanoma, RCC, Abstract (summary), Patient, TKI, BCR-ABL, CHB, Disease, CPI, GIST, Hepatitis, Cancer, Gist, MAPK, Therapy, Notifiable disease, Pharmaceutical industry

The AACR annual meeting is one of the world's largest and longest-standing scientific gatherings in the field of cancer research.

Key Points: 
  • The AACR annual meeting is one of the world's largest and longest-standing scientific gatherings in the field of cancer research.
  • Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community.
  • This year's AACR annual meeting will be held from April 14-19, 2023, in Orlando, Florida, USA.
  • Our results demonstrate the potential utility of combining alrizomadlin with MAPK pathway inhibitors to treat patients with uveal melanoma.

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

Retrieved on: 
星期二, 一月 3, 2023
Cancer, Standard of care, OS, International, Head, Food, Infection, Vulvar cancer, Merck, PDS, Platinum, Biotechnology, Neoplasm, Patient, Merck KGaA v. Integra Lifesciences I, Ltd., CPI-0610, PD-L1, FDA, Webcast, IL-12, Food and Drug Administration Amendments Act of 2007, Merck Group, Longevity, PDSB, National Cancer Institute, Neck, TGF, PARK, Palladium, Pharmaceutical industry, CPI

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. M9241 appears to enhance the proliferation, potency and longevity of T cells in the tumor. The combination of Versamune® and IL-12 is patented by PDS Biotech and is designed to overcome tumor immune suppression utilizing a different mechanism from checkpoint inhibitors.

Key Points: 
  • Under the terms of the agreement, PDS Biotech will receive from Merck KGaA, Darmstadt, Germany an exclusive license to M9241.
  • PDS Biotech will assume responsibility for future development, commercialization, and manufacturing of M9241.
  • “We are pleased to have partnered with Merck KGaA, Darmstadt, Germany to advance the development of M9241, a highly innovative cytokine therapy,” said Dr. Frank Bedu-Addo, PDS Biotech CEO.
  • “Under the licensing arrangement between Merck KGaA, Darmstadt, Germany and PDS Biotech, assumption of an equity stake by Merck KGaA, Darmstadt, Germany in PDS Biotech further confirms the potential of the Versamune® platform and the data generated to date with this combination therapy.

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

Retrieved on: 
星期三, 十二月 28, 2022
Cancer, OS, Head, NCI, Infection, Vulvar cancer, ORR, Platinum, Biotechnology, ASCO, AES, Patient, CPI-0610, Fourth grade, PD-L1, FDA, IL-12, CCR, Grade 3, Merck Group, PDSB, HPV, Neck, National Cancer Institute, TGF, American Society of Clinical Oncology, Society, Pharmaceutical industry, CPI

All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment.

Key Points: 
  • All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment.
  • The interim efficacy data (n=50) involves 37 HPV16-positive evaluable patients, including 29 patients who have, in addition, failed treatment with CPIs (CPI refractory).
  • The reported historical median OS in patients with CPI refractory disease is 3-4 months.
  • Historically median OS for similar patients with platinum experienced CPI naïve disease is 7-11 months.

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

Retrieved on: 
星期四, 十一月 10, 2022
RAF, GLOBE, CPI, Forward-looking statement, MAPK, Plasma, BIW, Risk, 3D, Colon, Annual general meeting, Immunotherapy, RAS, Biology, Perk, Mouse, Society for Immunotherapy of Cancer, MED, Half-life, Large-cell lung carcinoma, CTLA4, PD-1, U.S. Securities and Exchange Commission, Electric Bond and Share Company v. Securities and Exchange Commission, China Bio-Immunity Corporation, CPI-0610, BID, Cancer, CRC, Dual, Patient, TGI, Growth, NSCLC, MEK, Society, Chemistry, SITC, Pharmaceutical industry, Medical imaging, IND, Immune checkpoint

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today reported promising preclinical data in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, highlighting the activity of IMM-6-415, the company’s second program. IMM-6-415 is designed to target RAF and RAS mutant tumors as monotherapy and enhance therapeutic activity in select drug-drug combinations, including checkpoint inhibitors. The activity of IMM-6-415 is driven by an exceptionally short half-life that creates an accelerated cadence relative to the once-daily dosing of IMM-1-104.

Key Points: 
  • The activity of IMM-6-415 is driven by an exceptionally short half-life that creates an accelerated cadence relative to the once-daily dosing of IMM-1-104.
  • IMM-6-415 is tuned to provide an accelerated cadence of deep cyclic inhibition, since different cadences may be optimal for different biology.
  • We look forward to completing ongoing IND-enabling studies and expect to submit an IND for IMM-6-415 in Q4 2023.
  • Humanized 3D tumor models revealed a promising sensitivity profile for IMM-6-415 in RAF- and RAS-mutant models.

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Retrieved on: 
星期三, 六月 1, 2022
Docetaxel, CPI-0610, CFO, Biotechnology, ACTI, NAP, Neoplasm, CPI, Lymphatic system, Multiple myeloma, IIA, CEO, Partnership, Laquinimod, TTS, Therapy, Patient, Cancer, EU, NASDAQ, Communication, NSCLC, Naptumomab estafenatox, Pharmaceutical industry

The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling.

Key Points: 
  • The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling.
  • Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis.
  • Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors.
  • NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.

Achilles Therapeutics Announces Grant of US and European Patents

Retrieved on: 
星期三, 八月 25, 2021
Company, CNET, Invention, Large-cell lung carcinoma, GLOBE, Intention, Research, DNA, Drug discovery, Francis Crick Institute, ACHL, Therapy, UCL, CPI-0610, NASDAQ, Cancer research, Patient, NSCLC, CEO, Cancer Research UK, Professor, Patent, Technology, CPI, Pharmaceutical industry

The patents are based on data showing that patients with higher numbers of clonal neoantigens respond better to checkpoint inhibitor therapies1.

Key Points: 
  • The patents are based on data showing that patients with higher numbers of clonal neoantigens respond better to checkpoint inhibitor therapies1.
  • The patents are assigned to Cancer Research Technology and licensed exclusively to Achilles in certain fields.
  • Achilles continues to advance their development of precision T cell therapies for solid tumor cancers.
  • These patents are illustrative of the pioneering work that Achilles and Cancer Research UK have done in the field of clonal neoantigens, said Tony Hickson, Chief Business Officer of Cancer Research UK.

Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

Retrieved on: 
星期二, 四月 27, 2021
Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics, Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics, Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics

b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.

Key Points: 
  • b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.
  • The event will be webcast live and can be accessed on the Investor Relations section of Constellation\xe2\x80\x99s website at http://ir.constellationpharma.com/events-and-presentations/events.
  • The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance.
  • Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers.

Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Retrieved on: 
星期三, 一月 6, 2021
CPI-0610, BET inhibitor, EZH2, Pharmacology, Health care, Medicine

CAMBRIDGE,Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced thatJigar Raythatha, CEO, will present a company overview at theJ.P.

Key Points: 
  • CAMBRIDGE,Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced thatJigar Raythatha, CEO, will present a company overview at theJ.P.
  • Morgan Healthcare Conferenceat 10:50 AM ESTonThursday, January 14, 2021.
  • Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.
  • Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitorCPI-0209 for the treatment ofsolid tumors.

Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting

Retrieved on: 
星期一, 十一月 23, 2020
Primary myelofibrosis, CPI-0610, Cancer, Health, Clinical medicine, Medicine

This event will be webcast live and can be accessed on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events .

Key Points: 
  • This event will be webcast live and can be accessed on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events .
  • To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7164095.
  • MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the bodys normal production of blood cells.
  • Constellation Pharmaceuticalsis a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.